Atai Life Sciences N.V. (ATAI) Stock Price, Quote & News

Company Profile

Atai Beckley N.V., a clinical-stage biopharmaceutical company, engages in the research, development, and commercialization of mental health treatments in the United States, Germany, and Canada. The company develops BPL-003, an intranasal formulation of the benzoate salt form of mebufotenin that is in Phase 2a and 2b clinical studies for treatment resistant depression (TRD) and alcohol use disorder; RL-007, an orally bioavailable compound, which is a pro-cognitive neuromodulator in Phase 2b trial...

Industry: Biotechnology

Sector: Healthcare

Phone: 31 20 793 2536

Website: www.ataibeckley.com

Address:

Prof. J.H. Bavincklaan 7, Amstelveen, Netherlands

stoxx0007 Jan. 18 at 1:54 AM

$ATAI Major Institutions Buying ATAI recently:.... Morgan Stanley: Significantly increased its position to 4.8 million shares (a 38% increase). Citadel Advisors: More than doubled its stake (+118%), now holding 2.5 million shares. JPMorgan Chase: One of the most aggressive new buyers, increasing its position by over 5,000% in late 2025/early 2026. ARK Investment Management: Cathie Wood’s ARK Genomic Revolution ETF remains a top holder with 3.1 million shares.

0 · Reply

stoxx0007 Jan. 18 at 1:06 AM

$ATAI .... "AtaiBeckley being domiciled in the United States of America will also now make the company available for being included in multiple larges indices including the State Street SPDR S&P Biotech ETF (NYSE: XBI) and the Russell for the very first time, which could potentially unlock a significant amount of new buying and capital inflows"

0 · Reply

stoxx0007 Jan. 18 at 1:03 AM

$ATAI = ... DID YOU KNOW??? On January 12, 2026, Angermayer personally bought $2.52 million in ATAI shares. Couldn't resist these OVERSOLD levels 😃💥🔥💯

1 · Reply

thenewmoney Jan. 17 at 8:28 PM

Billionaire Christian Angermayer is one of the world’s most prolific entrepreneurs and investors in technology and biotech. And his psychedelic drug development company is on a mission to be on the leading edge of the psychedelic medicine revolution in America. $ATAI $CMPS https://www.thenew.money/article/christian-angermayers-ataibeckley-is-all-in-on-pyschedelic-medicines-in-america

0 · Reply

Mastacash Jan. 17 at 5:39 PM

$HELP, $ATAI, $MNMD, $CMPS, $GHRS. Check out my article on Psychedelics. We are just at the beginning. https://x.com/mastacash/status/2012560389712511287?s=12&t=jCHCXrWm93J_2H0pU9P1Fw

0 · Reply

Luvstocks26 Jan. 17 at 2:16 PM

$ATAI

0 · Reply

mwhite9869 Jan. 16 at 10:05 PM

$ATAI at this rate, my $TXMD position is going to be worth me than this. 🙄

0 · Reply

TommyDel Jan. 16 at 8:44 PM

$ATAI good long term but we really need to push above $4 again and start the climb back. I do find it hard to see the double digit numbers analysts have put but I am

0 · Reply

BigCatNY Jan. 16 at 8:03 PM

$ATAI yeah sad

0 · Reply

vlentini Jan. 16 at 7:52 PM

$ATAI Sanguinamento lento e continuo,un titolo deludente.

0 · Reply

AtaiBeckley Participates in the 64th Annual ACNP Meeting with Two Scientific Poster Presentations and Hot Topic Presentation

Jan 8, 2026, 7:00 AM EST - 9 days ago

AtaiBeckley Provides Update and Outlook for 2026 Ahead of J.P. Morgan Healthcare Conference

Dec 23, 2025, 7:00 AM EST - 25 days ago

AtaiBeckley Added to the Nasdaq Biotechnology Index (NBI)

Nov 19, 2025, 7:32 PM EST - 2 months ago

Enhanced Fortifies Executive Leadership Team & Board of Directors

Nov 11, 2025, 9:21 AM EST - 2 months ago

Atai Beckley N.V. (ATAI) Discusses BPL-003 Phase IIb Open-Label Extension Study Results in Treatment Resistant Depression Transcript

Oct 20, 2025, 5:29 PM EDT - 3 months ago

atai Life Sciences Announces Closing of Public Offering and Full Exercise of Option to Purchase Additional Common Shares

Oct 20, 2025, 9:00 AM EDT - 3 months ago

Atai Life Sciences And Beckley Psytech: Promising Emerging Leader In Psychedelics

Oct 16, 2025, 10:31 PM EDT - 3 months ago

atai Life Sciences Announces Pricing of Public Offering of Common Shares

Oct 16, 2025, 4:12 PM EDT - 3 months ago

atai Life Sciences Announces Proposed Public Offering of Common Shares

Oct 16, 2025, 4:10 PM EDT - 3 months ago

atai Life Sciences and Beckley Psytech Announce U.S. FDA Breakthrough Therapy Designation Granted to BPL-003, Underscoring its Potential in Treatment-Resistant Depression

Oct 13, 2025, 2:21 PM EDT - 3 months ago

Atai Life Sciences Remains Undervalued, Analyst Initiates With Around 125% Stock Upside

Oct 1, 2025, 2:40 PM EDT - 3 months ago

Atai Life Sciences: Still A Decent Prospect - But Only Just

Sep 23, 2025, 2:50 PM EDT - 4 months ago

Atai Life Sciences Experimental Depression Drug Shows Sustained Benefit In Treatment-Resistant Patients

Sep 23, 2025, 7:00 AM EDT - 4 months ago

atai Life Sciences and Beckley Psytech Report Positive Phase 2a Data Demonstrating Improved Outcomes with a Two-Dose Induction Regimen of BPL-003 in Patients with Treatment-Resistant Depression

Sep 9, 2025, 6:59 AM EDT - 4 months ago

Atai Life Sciences N.V. (ATAI) Presents at H.C.

Aug 28, 2025, 4:05 PM EDT - 5 months ago

atai Life Sciences to Participate in September Investor Conferences

Jul 28, 2025, 5:01 PM EDT - 6 months ago

Atai: Inidascamine Trial Failure Doesn't Matter In Main Psychedelic Pipeline Focus

Jul 28, 2025, 10:58 AM EDT - 6 months ago

Why Is ATAI Life Sciences Stock Trading Lower On Monday?

Jul 28, 2025, 8:13 AM EDT - 6 months ago

ATAI Life Sciences, Revvity And Other Big Stocks Moving Lower In Monday's Pre-Market Session

RVTY

Jul 25, 2025, 4:16 PM EDT - 6 months ago

Atai Life Sciences schizophrenia drug fails to meet main goal in mid-stage trial

Jul 25, 2025, 4:05 PM EDT - 6 months ago

Recognify Life Sciences Provides Update on Phase 2b Trial of Inidascamine in Patients with Cognitive Impairment Associated with Schizophrenia

Jul 2, 2025, 2:29 PM EDT - 7 months ago

Atai: Critical Study Win Sets Up Double Approval Shot For Psychedelics In TRD

Jul 1, 2025, 9:28 AM EDT - 7 months ago

Atai Life Sciences And Merger Partner Set Up Psychedelic Depression Therapy With Encouraging Late-Stage Data

Jul 1, 2025, 6:05 AM EDT - 7 months ago

atai Life Sciences Announces $50 Million Private Placement Financing

Jul 1, 2025, 6:00 AM EDT - 7 months ago

atai Life Sciences and Beckley Psytech Announce Positive Topline Results from the Phase 2b Study of BPL-003 in Patients with Treatment-Resistant Depression

Jun 2, 2025, 6:00 AM EDT - 8 months ago

atai Life Sciences and Beckley Psytech to Combine Creating a Global Leader in Psychedelic Mental Health Therapies

May 29, 2025, 8:30 AM EDT - 8 months ago

atai Life Sciences to Participate in Upcoming Investor Conferences

May 20, 2025, 7:00 AM EDT - 8 months ago

atai Life Sciences Announces Positive Topline Data from Part 2 of Beckley Psytech's Phase 2a Study of BPL-003 in Combination with SSRIs for Treatment-Resistant Depression

May 14, 2025, 7:00 AM EDT - 8 months ago

atai Life Sciences Reports First Quarter 2025 Financial Results and Recent Corporate Updates

May 13, 2025, 7:01 AM EDT - 8 months ago

atai Life Sciences Announces First Patient Dosed in Phase 2 Study of EMP-01 for the Treatment of Social Anxiety Disorder

Mar 11, 2025, 7:00 AM EDT - 11 months ago

atai Life Sciences Announces First Patient Dosed in Elumina, the Phase 2 Clinical Trial of VLS-01 for Treatment-Resistant Depression

Feb 27, 2025, 12:45 PM EST - 11 months ago

Atai: Following The Path That Spravato Laid And Moving Beyond It

Feb 24, 2025, 4:10 PM EST - 11 months ago

atai Life Sciences to Participate in the TD Cowen 45th Annual Health Care Conference

Jan 29, 2025, 11:57 AM EST - 1 year ago

Atai Life Sciences: Positive BPL-003 Data In AUD Leads To Another Catalyst

Jan 10, 2025, 7:00 AM EST - 1 year ago

atai Life Sciences Announces Key Leadership Appointments as it Advances its Pipeline of Novel Psychedelic Therapeutics for Mental Health

Oct 2, 2024, 9:21 AM EDT - 1 year ago

IntelGenx is Granted Court Approval of the Sale Proposal from atai Life Sciences AG

Sep 4, 2024, 7:00 AM EDT - 1 year ago

atai Life Sciences to Participate in the H.C. Wainwright 26th Annual Global Investment Conference

Sep 3, 2024, 2:00 PM EDT - 1 year ago

Psychedelic Stock Deep Dive: Atai Life Sciences

Aug 13, 2024, 7:10 AM EDT - 1 year ago

atai Life Sciences Reports Second Quarter 2024 Financial Results and Provides Corporate Updates

Aug 12, 2024, 12:12 PM EDT - 1 year ago

Psychedelic drug contender stocks drop after FDA rejects MDMA treatment

CMPS DFTX

Aug 7, 2024, 7:00 AM EDT - 1 year ago

atai Life Sciences to Participate in the Canaccord Genuity 44th Annual Growth Conference

Jun 26, 2024, 7:00 AM EDT - 1 year ago

atai Life Sciences to Participate in the H.C. Wainwright 5th Annual Neuro Perspectives Conference

Jun 20, 2024, 7:00 AM EDT - 1 year ago

atai Life Sciences Announces Update on Beckley Psytech's Phase 1/2a Trial of ELE-101 (IV Psilocin) for Major Depressive Disorder, with Initial Results from Phase 1 and First Patients Dosed in Phase 2a

May 31, 2024, 7:00 AM EDT - 1 year ago

atai Life Sciences to Participate in the Jefferies 2024 Global Healthcare Conference

May 15, 2024, 6:59 AM EDT - 1 year ago

atai Life Sciences Reports First Quarter 2024 Financial Results and Corporate Updates

Apr 24, 2024, 7:00 AM EDT - 1 year ago

atai Life Sciences Announces Dosing of First Patient in Part 2 of Beckley Psytech's Phase 2a Study Exploring BPL-003 Adjunctive to SSRIs in Patients with Treatment Resistant Depression

Apr 17, 2024, 7:00 AM EDT - 1 year ago

atai Life Sciences Announces the Publication of Beckley Psytech's Phase 1 Study of BPL-003 in the Journal of Psychopharmacology

Mar 28, 2024, 7:00 AM EDT - 1 year ago

atai Life Sciences Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Corporate and Clinical Highlights

Mar 27, 2024, 7:00 AM EDT - 1 year ago

atai Life Sciences Announces Positive Initial Results from Beckley Psytech's Phase 2a Open Label Study of BPL-003 (Intranasal 5-MeO-DMT) in Treatment Resistant Depression

stoxx0007 Jan. 18 at 1:54 AM

0 · Reply

stoxx0007 Jan. 18 at 1:06 AM

0 · Reply

stoxx0007 Jan. 18 at 1:03 AM

$ATAI = ... DID YOU KNOW??? On January 12, 2026, Angermayer personally bought $2.52 million in ATAI shares. Couldn't resist these OVERSOLD levels 😃💥🔥💯

1 · Reply

thenewmoney Jan. 17 at 8:28 PM

0 · Reply

Mastacash Jan. 17 at 5:39 PM

$HELP, $ATAI, $MNMD, $CMPS, $GHRS. Check out my article on Psychedelics. We are just at the beginning. https://x.com/mastacash/status/2012560389712511287?s=12&t=jCHCXrWm93J_2H0pU9P1Fw

0 · Reply

Luvstocks26 Jan. 17 at 2:16 PM

$ATAI

0 · Reply

mwhite9869 Jan. 16 at 10:05 PM

$ATAI at this rate, my $TXMD position is going to be worth me than this. 🙄

0 · Reply

TommyDel Jan. 16 at 8:44 PM

$ATAI good long term but we really need to push above $4 again and start the climb back. I do find it hard to see the double digit numbers analysts have put but I am

0 · Reply

BigCatNY Jan. 16 at 8:03 PM

$ATAI yeah sad

0 · Reply

vlentini Jan. 16 at 7:52 PM

$ATAI Sanguinamento lento e continuo,un titolo deludente.

0 · Reply

MoneyGroupLLC Jan. 16 at 5:29 PM

Enter: $ATAI Calls Strike Price: $4 Expiry Date: FEB 20 2026 Buy in Price: $0.35 - $0.70 Sell Price: $0.61 Profit : +73% (Turn every $1 into $1.73) Want Profitable Real-Time Options Alerts? 👉 https://moneygroup.us/

0 · Reply

Luvstocks26 Jan. 16 at 3:19 PM

$IBRX Number one, $GME $OPEN $ATAI $BYND

0 · Reply

vlentini Jan. 16 at 2:49 PM

$ATAI Titolo che scende in continuazione, sempre nuovi minimi e alcuni qua che lo lodano per la prospettiva a lungo termine, probabilmente è solo infatuazione,il mercato evidentemente non crede.

0 · Reply

PreGigs Jan. 16 at 2:43 PM

$ATAI I'm tempted to pull some of this out and go on vacation - any idea when this might go up instead of down?

2 · Reply

macrossluvsrobotech Jan. 15 at 9:45 PM

$CMPS Will be the first to market. RFK Jr, will unleash this. Topline will be good. Topline in June was EXCELLENT. IT WORKS. All this pending phase 3 comp006 will tell us is dosing. RFK Jr will greenlight this so godamn fast. That event in January, the commercialization. Radial putting in their own money to get the offcices ready. The Hercules Loan, assuring solid 2026-2027 supply of liquidity, with ZERO need for more money. I don't understand why anybody here would even fathom a 6 dollar and change entry here. It's not going to happen. IF YOU WANT TO KNOW WHAT'S GOING TO HAPPEN IN THE NEAR FUTURE UNDE THIS ADMINISTATION? JUST WATCH THE FOLLOWING VIDEO, AND ASK YOURSELF WHO HEADS THE FDA NOW. https://youtu.be/4V7C_bdsu1Q?si=rpOD-fRVVLWvZcOJ $ATAI $MNMD $IBB $BIB

2 · Reply

FLNY Jan. 15 at 4:30 PM

$ATAI

0 · Reply

matrixtrade123 Jan. 15 at 3:21 PM

$ATAI need some news that We Can BITE ON It !

0 · Reply

Hanaleimike Jan. 15 at 3:17 PM

$ATAI anyone recognize this action? Everyday, same thing

1 · Reply

moneygrabber55 Jan. 15 at 2:43 PM

$ATAI was that just a big green candle?

0 · Reply

Luvstocks26 Jan. 15 at 2:01 PM

$ATAI This one is a gem

1 · Reply

Mastacash Jan. 15 at 5:01 AM

$HELP Broke out of the 2 year long downtrend, retested and bounced of the trendline and 200dma. Consolidation here would be welcome, it will set up a monster move soon. 🚀 I can’t find a better catch up trade in the market. Peers $MNMD $ATAI $GHRS $CMPS all with billion dollar or more market caps. $HELP is going to 3x in a hurry.

1 · Reply

Schaf Jan. 15 at 1:19 AM

$ATAI I have no special insight. But my gut is that we’re looking at a patience play. Questions for introspection: Is TRD a multibillion dollar category? Do you believe this treatment category is efficacious? Do you believe the administration will support commercialization? Do you believe that ATAI has a preferred delivery mechanism? Do you think this company is responsibly operated and capitalized? Are there secondary pipeline drugs that you consider interesting? It’s passing a lot of test gates for me. Its cheap. I think we’re looking at 10-20x upside. You do you.

1 · Reply

Market Cap	1.25B
Revenue (ttm)	310,000.00
Net Income (ttm)	-149.27M
EPS (ttm)	N/A
PE Ratio	0.00
Forward PE	N/A
Profit Margin	-48,151.61%
Debt to Equity Ratio	0.00

Volume	10,284,041
Avg Vol	5,985,524
Day's Range	N/A - N/A
Shares Out	233.78M
Stochastic %K	10%
Beta	1.59
Analysts	Strong Sell
Price Target	$12.12